Genetic Carrier Screen, (CF, FXS, and SMA) with Reflex to Methylation

3000258
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive

Icon

Informed Consent for Genetic Testing (required for NY patients)

Icon

Additional Technical Information

Icon

Patient History for CF, FXS and SMA Carrier Screening

Ordering Recommendation

Carrier screening for cystic fibrosis (CF), fragile X syndrome (FXS), and spinal muscular atrophy (SMA) in women who are pregnant or planning a pregnancy. Not recommended for men, as FXS carrier screening is not indicated. Do not use for diagnostic testing in patients with symptoms of CF, FXS or SMA. For CF carrier screening alone, refer to Cystic Fibrosis (CFTR) Expanded Variant Panel (2013661). For SMA carrier screening alone, refer to Spinal Muscular Atrophy (SMA) Copy Number Analysis (2013436). For FXS carrier screening alone, refer to Fragile X (FMR1) with Reflex to Methylation Analysis (2009033).

Mnemonic

CF FX SMA

Methodology

Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry/Polymerase Chain Reaction/Capillary Electrophoresis/Multiplex Ligation-Dependent Probe Amplification

Performed

Sun-Sat

Reported

4-14 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Lavender (K2EDTA). Also acceptable: Pink (K2EDTA).

Specimen Preparation

Transport 5 mL whole blood. (Min: 3 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or serum. Specimens collected in sodium heparin, yellow (ACD solution A), or lithium heparin tubes. Frozen specimens in glass collection tubes.

Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month

Reference Interval

By report

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Note

Cystic Fibrosis (CF): The Cystic Fibrosis (CFTR) Expanded Variant Panel includes the 23 pathogenic CF variants recommended by the American College of Medical Genetics for population carrier screening as well as many others.

Fragile X:  If a CGG repeat of 100 or greater is detected by PCR and Capillary Electrophoresis; methylation analysis will be added. Additional charges apply.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
05/16/2022
X
X
X
X
05/17/2021
X
N/A

CPT Codes

81220; 81329; 81243; if reflexed, add 81244

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0050556 Fragile X Allele 1 45321-7
0050558 Fragile X Allele 2 45322-5
0050559 Fragile X Methylation Pattern 41107-4
0050579 Fragile X Interpretation 36913-2
2001310 FRAG X Specimen 66746-9
2013437 SMA Copy Number, Specimen 31208-2
2013438 SMA Copy Number, Symptoms 75325-1
2013439 SMA Copy Number, SMN1 Copies 35462-1
2013440 SMA Copy Number, SMN2 Copies 54449-4
2013441 SMA Copy Number, Linked Variant 82155-3
2013442 SMA Copy Number, Int 49857-6
2013675 Cystic Fibrosis, Allele 1 42938-1
2013676 Cystic Fibrosis, Allele 2 42939-9
2013677 CF Expanded Variant Panel Interp 21656-4
2013692 Cystic Fibrosis 5T Variant 21654-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • CF
  • CFTR
Genetic Carrier Screen, (CF, FXS, and SMA) with Reflex to Methylation